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Summary Chimeric antigen receptor (CAR) T-cells
are genetically engineered to give T-cells the ability
to attack specific cancer cells, and to improve out-
come of patients with refractory/relapsed aggressive
B-cell malignancies. To date, several CAR T-cell prod-
ucts are approved and additional products with sim-
ilar indication or extended to other malignancies are
currently being evaluated. Side effects of CAR T-cell
treatment are potentially severe or even life-threat-
ening immune-related toxicities, specifically cytokine
release syndrome (CRS) and immune effector cell-
associated neurotoxicity syndrome (ICANS). Conse-
quently, medical emergency teams (MET) are increas-
ingly involved in the assessment and management of
CAR T-cell recipients. This article describes the princi-
ples of CAR T-cell therapy and summarizes the main
complications and subsequent therapeutic interven-
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Background
The armamentarium of cancer therapies has rapidly
evolved within the past two decades. Among recent
approaches, targeting the patient’s immunologic self-
defence and enhancing T-cell responses represent
very promising developments. Checkpoint inhibitors,
chimeric antigen receptor (CAR) T-cells, and bis-
pecific antibodies attack cancer cells by activating
immune effectors and/or decreasing their immune
tolerance making them more vulnerable to the effects
of immune system cells [1].
To date, several CAR T-cell products, e.g. tis-
agenlecleucel (Kymriah®), axicabtagene ciloleucel
(Yescarta®), brexucabtagene autoleucel (Tecartus®),
and lisocabtagene maraleucel (Breyanzi®) are on the
market, although some of them not yet approved
by the European Medicines Agency (EMA). Most of
them are targeting the CD19 antigen, expressed by
most B-cell malignancies [2–6]. In patients with
relapsed or refractory (r/r) large B-cell lymphoma
and patients with mantle cell lymphoma, CAR T-cell
therapies have been shown to induce a temporary
or even durable complete remission in the major-
ity of patients [4, 5, 7]. In patients with relapsed
B-ALL following allogeneic hematopoietic stem cell
transplantation, CAR-T cell therapy provides the only
curative approach [6]. In March this year, the first
CAR-T cell product against multiple myeloma (ide-
cabtagene vicleucel) has been approved, targeting the
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B cell maturation antigen (BCMA) [8]. In the coming
months and years, approvals for additional CAR-T
cell products for these indications and other B-cell
malignancies are expected.
After CAR-T cell administration, patients can de-
velop specific acute toxicities, namely cytokine release
syndrome (CRS) [9–12] or immune effector cell-asso-
ciated neurotoxicity syndrome (ICANS) [10, 12], that
can vary from minor transient symptoms up to life-
threatening conditions. Therefore, early recognition
by the oncologic team with timely involvement of crit-
ical care teams, i.e. medical emergency teams (MET),
is crucial. This review article is a survival guide for
METs with a summary of the key toxicities associated
with CAR-T cell therapy and a proposal for a manage-
ment algorithm.
Principles of CAR T-cell therapy
Autologous CAR-T cells are “living drugs” and are tai-
lor-made for each individual patient. Therefore, a va-
riety of logistic challenges and a complex produc-
tion process precede CAR-T cell treatment [13]. In
many instances, bridging strategies including cyto-
toxic compounds, B-cell antibodies, or radiotherapy,
are needed to control the B-cell malignancy before
the patient enters CAR-T cell therapy. Prior to CAR-T
cell infusion, patients receive lymphocyte-depleting
chemotherapy, to ensure tolerance and persistence of
the administered CAR-T product [2]. In the weeks
(and sometimes months) following CAR-T cell infu-
sion, both CD19 and BCMA directed CAR-T cells show
a wide range of interindividual expansion and prolif-
eration dynamics in the recipient and subsequently
exert their effects towards the malignant B-cell tissues
as well as the healthy B-cell compartment.
Key toxicities related to CAR T-therapy
The American Society for Transplantation and Cellu-
lar Therapy (ASTCT) developed a recommendation for
definition and grading for CAR T-related toxicity (Ta-
ble 1; [10]). The grading systems are incorporated
and easy to calculate on the CARTOX app, which has
been developed by the MD Anderson Cancer Center
in the USA [14]. The incidence and severity of CAR
T-related toxicities are likely associated with high dis-
ease burden, a higher peak of CAR-T cell expansion in
the peripheral blood, and high baseline inflammatory
activity [11, 15–18]. Side effects of CAR-T cell ther-
apy seems to be more pronounced in patients with
ALL as compared to DLBCL [4, 6]. Studies in patients
treated for ALL reported a significant correlation be-
tween neurotoxicity and the presence of CRS as well
as its severity [18]. In addition, the different CAR-T
cell products have different rates of toxicities: Axicab-
tagene ciloleucel causes higher rates of ICANS than
tisagenlecleucel [3, 4, 19].
Cytokine release syndrome (CRS)
The CRS is the most common acute toxicity following
CAR-T cell therapy with a reported incidence between
37% and 93% across different studies. [3, 4, 6, 20, 21].
The onset of CRS typically occurs within hours up to
4–7 days after CAR-T cell infusion, but late occurrence
up to 14 days has also been reported [3, 4, 6, 20, 22].
The CRS is characterized by excessive immune re-
action triggered by various factors, such as infections
and immune-modulating drugs, in particular T-cell
engaging treatment strategies [17, 23].
Increased IL-6 levels correlate with the onset of se-
vere CRS symptoms [24] and seem to play a key role
in CRS pathophysiology, as they are higher in patients
with CRS than in patients without [25–28]. To date,
there is no evidence that T-cells or CAR-T cells are
a significant source of IL-6 production [29, 30].
The leading symptom is fever, defined as ≥38.0 °C,
and is required for a diagnosis of CRS [10]. Other
nonspecific symptoms, includingmalaise, myalgia, fa-
tigue, gastrointestinal complaints (nausea, vomiting,
diarrhea), tachycardia, and rash, may also be present
[9, 16, 17, 31]. The CRS may be self-limiting and can
resolve with supportive care alone ormay become life-
threatening with capillary leak leading to pulmonary
edema, hypotension, multiorgan failure, and circula-
tory collapse [9, 20], see also Table 1.
Immune effector cell-associated neurotoxicity
syndrome (ICANS)
The ICANS was reported to become manifest in
around 40% of CAR-T cell recipients [32]. The on-
set of neurotoxicity typically occurs after the start of
CRS, and sometimes even after CRS has completely
resolved [18]. Typically, ICANS becomes clinically
manifest within 4–10 days following CAR-T cell infu-
sion [3, 4, 20].
The mechanisms underlying CAR-T cell-related
neurotoxicity are not yet fully understood but disrup-
tion of the brain-blood barrier and cerebral edema
via cytokine release by CAR-T seem to be key features
of ICANS [3, 18]. In up to 95% of patients, CAR-T
cells could be detected in the cerebrospinal fluid
(CSF); however, the numbers did not correlate with
the severity of ICANS as they could also be found in
patients without neurological pathology [18, 33].
Patients with ICANS often develop a characteris-
tic sequence of neurologic symptoms [10, 31], with
tremor, dysgraphia, mild expressive aphasia, apraxia
and impaired attention in the initial phase. Partic-
ularly, expressive aphasia evolving over a period of
hours to global aphasia has been reported as a spe-
cific symptom [18]. This characteristic finding of an
awake patient who is mute and unable to follow com-
mands distinguishes ICANS from other causes of en-
cephalopathy [31]. Furthermore, neurotoxicity can
CAR T-cell therapy and critical care K
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Table 1 ASTCT CRS and ICANS consensus grading for adults [10]
Grade 1 Grade 2 Grade 3 Grade 4
CRS parameter
Fevera ≥38.0 ≥38.0 ≥38.0 ≥38.0
With











mask, or venturi mask
Requiring positive pressure
(e.g. CPAP, BiPAP, and me-
chanical ventilation)
Neurotoxicity domain
ICE scoreb 7–9 3–6 0–2 0
(patient is unarousable and
unable to perform ICE)
Depressed level of conscious-
ness
Awakens spontaneously Awakens to voice Awakens only to tactile stimu-
lus
Patient is unarousable or
requires vigorous or repetitive
tactile stimuli to arouse. Stupor
or coma
Seizure N/A N/A Any clinical seizure, focal or
generalized, that resolves
rapidly or non-convulsive
seizures on EEG that resolve
with intervention
Life-threatening prolonged
seizure (>5min); or repetitive
clinical or electrical seizures
without
return to baseline in between
Motor findings N/A N/A N/A Deep focal motor weakness
such as hemiparesis or para-
paresis
Elevated ICP/cerebral oedema N/A N/A Focal/local edema on
neuroimaging
Diffuse cerebral oedema on
neuroimaging; decerebrate
or decorticate posturing; or
cranial nerve VI
palsy; or papilledema; or Cush-
ing’s triad
ASTCT American Society for Transplantation and Cellular Therapy, CRS cytokine release syndrome, ICANS immune effector cell-associated neurotoxicity syn-
drome, CPAP Continuous Positive Airway Pressure Therapy, BiPAP Bilevel Positive Airway Pressure Therapy
aFever is the sole symptom required for classification as grade 1. In patients who have CRS who undergo antipyretic or anticytokine therapy (tocilizumab or
steroids), fever is no longer required to grade subsequent CRS severity, CRS grading is then defined by hypotension and/or hypoxia
bICE immune effector cell-associated encephalopathy score: 1 point for each: year, month, name city, hospital, one point for every object correctly identified
(max. 3 points), follow command, write a standard sentence, and count backwards from 100 by 10. Score of 10: no impairment. CRS and ICANS grades are
determined by the most severe event not attributable to any other cause
proceed to diffuse cerebral edema with subclinical or
clinical seizures [10].
For the assessment and grading of CAR-related en-
cephalopathy, the so-called immune effector cell-as-
sociated encephalopathy (ICE) score has been devel-
oped [10]. The latter score has recently replaced the
CARTOX-10, both scores incorporate key elements of
the mini-mental state examination and evaluate alter-
ations in speech, orientation, handwriting, and con-
centration (Table 1; [10]).
Important differential diagnoses
Due to the similarity of symptoms and the immuno-
suppressed state of the patient it is crucial to exclude
sepsis and treat infections appropriately. In a recent
study on outcomes in critically ill CAR T recipients,
sepsis was one of the main reasons for ICU admission
[34]. Sepsis-related encephalopathy and meningi-
tis/encephalitis can mimic ICANS. Moreover, severe
CRS has been associated with a higher infection
risk [35]. The reason for this association is unclear:
high cytokine levels, immunosuppressive therapies,
aggressive supportive care, and intensive care unit
(ICU) management might play a role. Tumor lysis
syndrome can usually be distinguished by typical
laboratory findings, such as hyperuricemia, hyper-
kalemia, hypocalcemia, and hyperphosphatemia [36];
however, tumor lysis syndrome and CRS may occur
coincidentally [37]. Furthermore, the progression of
the underlying malignancy may cause tumor-associ-
ated fever and other clinical, metabolic, and imaging
abnormalities that resemble those of CRS. CRS is rem-
iniscent of macrophage activation syndrome (MAS) as
well as hemophagocytic lymphohistiocytosis (HLH).
Both represent syndromes with dysregulated immune
response resulting in a severe cytokine storm, hence
laboratory findings and the cytokine profile are closely
related betweenMAS/HLH and severe CRS [38]. Thus,
MAS/HLH might be regarded as consequence of CRS
and CAR-T cells acting as a trigger for subsequent
development of HLH/MAS [39]. In addition, fungal
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infections as well as fulminant relapses of the un-
derlying disease might be triggers for HLH/MAS [40],
which is why consistent and repeated investigation
are important once a diagnosis of HLH following
CAR-T therapy has been established.
Hypersensitivity reactions may appear after CAR
T infusions and typically present with rash and ur-
ticaria, fever, dyspnea, hypotension, and gastroin-
testinal symptoms and eventually cardiorespiratory
failure. Considering ICANS, important differential
diagnoses are intracranial bleeding (especially when
thrombocytopenia is present) or stroke. ICANS can
result in epileptic seizures, which have to be identified
in an electroencephalogram (EEG), especially when
nonconvulsive.
Management of CAR T-cell-related toxicities
Timely recognition and interdisciplinary management
are key components for the management of patients
developing CAR T-related toxicities. The CARTOX
group recommends a grade-based management ap-
proach for CRS and neurologic toxicity [9, 10, 15].
According to these guidelines and management rec-
ommendations, lower grade ICANS and CRS can be
managed on the ward with supportive and/or phar-
macologic therapy. Management of early stages of
CRS and ICANS (grade 1–2) includes ruling out in-
fections and other important differential diagnoses.
Whilst most of the patients respond well to sup-
portive care including antipyretics and intravenous
fluid hydration, early administration of tocilizumab
in patients with lower grade CRS may be increasingly
considered standard of care. With respect to ICANS,
swallowing assessment and aspiration precautions are
recommended. Additionally, cerebral imaging (prefer-
ably MRI [21]) and EEG should be considered [41].
In the absence of seizures, prophylactic levetirac-
etam is recommended [9, 21, 42], but the duration
and dose have not yet been determined. In general,
an early strong collaboration between MET, hemato-
oncologists, neurologists and other organ specialists
is crucial. Therefore, at our centr we adapted cur-
rent CAR T-related toxicity guidelines and developed
a concise algorithm to be used by our MET (Fig. 1).
Criteria for ICU admission
In general, patients with higher (≥3) grade of toxicity
(see also Table 1) should be managed on the ICU [9,
10, 15, 16, 43]. Thus, patients requiring one or more
organ support or have a reduced level of conscious-
ness fulfil the criteria for ICU admission [10, 16]; how-
ever, a recently published survey evaluating ICUman-
agement of CAR-T cell-associated toxicities revealed
that a majority of ICU admitted patients presented
with CRS grade 1–2 (73%) and ICANS grade 2 (81%)
[44]. In this survey, reasons for admitting lower grade
toxicities were concerns for later deterioration, need
for further interventions, concerns for evolving non-
cardiogenic pulmonary edema, or risk for rapid dete-
rioration due to large tumor burden [10]. The CART-
TAS trial investigating outcomes in patients treated
with CAR-T cells revealed that about 30% of the pa-
tients required admission to ICU, all for CRS, ICANS,
or sepsis [34].
Intensive care management
Supportive management of organ dysfunction or fail-
ure follows respective standard intensive care guide-
lines [11, 31]. The CAR-ICU survey has shown that
management practices are very similar amongst par-
ticipating units [44]. For the fluid management, most
units use repetitive fluid bolus of 4ml/kg BW, and fluid
responsiveness was assessed with noninvasive modes
(stroke volume variation, cardiac output, ultrasound
guided). Early experience has shown that treating
persistent hypotension in CRS with overt fluid man-
agement was inferior to early vasopressors use [10].
First line vasopressor in most units is noradrenaline,
followed by vasopressin and epinephrine [44]. For
patients with respiratory failure, most units perform
a noninvasive ventilation trial before intubation [44].
In patients with prolonged severe CRS (persisting
for >72h without response to intervention), a car-
diac assessment, including cardiac biomarkers (e.g.
troponin, NT-proBNP/BNP) or the performance of
a echocardiography, is recommended [21]. For pa-
tients with neurotoxicity, along with neuroprotective
measurements, more invasive intracranial pressure
monitoring and enhanced neuroprotective treatment
(hypertonic saline, mannitol, pharmacological coma)
might be necessary [9, 15, 45, 46]. Nonconvulsive and
convulsive status epilepticus should be managed with
benzodiazepines and additional antiepileptic drugs,
preferably levetiracetam, followed by phenobarbital
[9]. As sepsis at ICU admission might be an important
determinant of mortality in this patient population,
particularly when they are neutropenic, screening for
infections and commencing broad-band antibiotics
has to be considered [34].
Specific therapies
Corticosteroids are immunosuppressive and are ef-
fective in the management of CRS and ICANS [11,
16, 47]. Intravenous corticosteroids are the first-line
therapy for patients with ICANS ≥grade 2 [18], while
in CRS they are used for second-line in case of re-
fractory symptoms. Recent recommendations even
suggested to add steroid in cases of severe CRS not
responding to first dose of tocilizumab [21]; however,
the evidence for this is not sound and therefore needs
to be considered individually In both CRS and ICANS,
methylprednisolone (2mg/kg and day) or dexam-
ethasone (0.5mg/kg, maximum 10mg) are commonly
used steroids. To avoid jeopardizing CAR-T cell func-
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review article
Criteria for ICU Admission
• SBP < 90 mmHg refractory to IV fluid challenge requiring vasopressors OR
• Hypoxia/respiratory distress with incrasing oxygen requirement (≥ 6L O2/min) or 
need for ventilatory support OR
• ECG changes and/or clinically significant arrhythmias, acute coronary syndrome 
with positive troponin OR
• ICE-Test ≤ 6 points, signs of raised ICP, OR seizures
• Team concern
None of the 
Signs
Diagnostic work-up: 
















with 2nd dose of tocilizumab
Increase dexamethasone
Dose
(consider high dose 
Steroids)
Taper dose 




• Supportive management of organ toxicities as per standard guidelines
• Assess for infection (blood/urin cultures, chest x-ray, ICANS: lumbar puncture, 
and start empiric antibiotic therapy
• Laboratory: Renal, liver markers, full blood count, LDH, consider ferritin
• Consider echocardiography (recommended for prolonged severe CRS >72h)
• ICANS: cCT/MRI, EEG, neuroprotective care, consider ICP monitoring














Worsening ICANS within 
12 hours 
OR








Tocilizumab: 8mg/kg bw., max. every 8 hours
Steroids: Methylprednisolone (2mg/kg/day) or 
dexamethasone (0.5mg/kg bw, max. 10mg/
dose), high dose steroids: >100mg daily of 
prednisone equivalent
Fig. 1 Medical emergency team (MET) algorithm for the as-
sessment and management of CAR-T related toxicities. Algo-
rithm adapted from Lee et al. [10], Park et al. [12], and Maus
et al. [21]. CRS cytokine release syndrome, ICANS immune
effector cell-associated neurotoxicity syndrome, ICE immune
effector cell-associated encephalopathy, cCT cerebral com-
puted tomography, MRI magnetic resonance imaging, ICP in-
tracranial pressure, LDH lactate dehydrogenase, EEG elec-
troencephalogram
K CAR T-cell therapy and critical care
review article
tion, the initial recommendation of steroid use was
limited to patients with CRS refractory to anti-IL-6
therapy or patients with grade 3–4 CRS toxicities [9].
Today, however, this concern turns out to be unjusti-
fied [46, 48–50]. Once CRS symptoms are improving,
steroids should be gradually tapered off [21].
Tocilizumab, an IL-6R antagonist, represents the
first-line immunosuppressive therapy of CRS [16]. It
binds both the soluble and the cell-associated IL-6
receptor. In several studies, tocilizumab has proven
to be effective for severe or life-threatening CRS,
and usually patients with CRS rapidly respond to
tocilizumab—fever and hypotension often resolve
within a few hours [51, 52]; however, considera-
tions have been given to use tocilizumab pre-emp-
tively or even as prophylaxis, as blocking IL-6 with
tocilizumab neither significantly compromised ther-
apeutic efficacy of CAR-T cells, nor did it negatively
affect prognosis of the CAR-T cell recipients [3, 9, 48,
53]. For patients with isolated ICANS, tocilizumab
was shown to be ineffective and should only be ad-
ministered in patients with concurrent CRS [18, 30,
32]. This might be due to the fact that tocilizumab
does not cross the blood-brain barrier [16]; however,
IL-6 is likely involved in the pathogenesis of CAR T-
related neurotoxicity and levels of IL-6 have shown to
rise transiently following tocilizumab administration,
which might lead to an aggravation of neurologic
symptoms [16].
Siltuximab is a direct IL-6 antagonist and has simi-
lar effects as tocilizumab. Siltuximab might have a fa-
vorable outcome in the case of passive diffusion of
IL-6 into the CNS [9]; however, a randomized prospec-
tive comparison between siltuximab and tocilizumab
is still missing [9] and siltuximab has not yet been ap-
proved for this indication by US and European drug
agencies (FDA and EMA).
For therapy refractory CRS, the addition of third
line therapies has been suggested [21]; however, these
therapies are currently considered investigational.
Whereas IL-6 blockade prevents mainly CRS, the
additional IL-1 blockade achieved with the use of
anakinra could potentially prevent both CRS and
ICANS [30]. A recent report suggested that anakinra
could be a potential steroid-sparing strategy for the
treatment of CAR T-cell therapy-associated toxicities,
mainly ICANS. Several clinical trials investigating its
early and/or prophylactic use are ongoing [54].
Conclusion
In parallel with the introduction of potentially curative
CAR-T cell therapies, the spectrum of unique toxici-
ties is growing as well. Tocilizumab is the mainstay
pharmacologic therapy for CRS, while corticosteroids
should be reserved for neurologic toxicities and CRS
not responsive to tocilizumab. An established multi-
disciplinary collaboration between dedicated hemato-
oncologists, organ specialists and critical care physi-
cians is crucial in the management of these patients.
Improved knowledge of CAR-T related toxicities, and
development of new pharmacological options, es-
pecially for prevention and therapy of ICANS, will
hopefully further increase safety and practicability of
CAR-T cell application in the near future.
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